Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Mød ledelsen i Gubra, og stil spørgsmål til dagens investorpræsentation

By Rasmus KøjborgHead of Research, Stables
Gubra

Den 9. marts offentliggjorde AbbVie positive topline-resultater fra fase 1-forsøget for ABBV-295 - Gubras udlicenserede langtidsvirkende amylin-analog. I forbindelse med disse data afholder vi et live-event i dag kl. 13.30 med CFO Kristian Borbos og IR- og strategichef Emma Jappe Lange fra Gubra, som vil præsentere data og resultaterne fra studiet. Efter præsentationen vil der være en spørgerunde. Tilmeld dig og stil dine spørgsmål allerede nu: https://www.inderes.dk/videos/gubra-presentation-of-phase-1-topline-results-on-abbv-295-long-acting-amylin-analog

Disclaimer: HC Andersen Capital modtager betaling fra de nævnte selskaber for en digital IR abonnementsaftale. /Rasmus Køjborg, CFA d. 10/03-2026 kl. 09:35.

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.